GLP-1 agonists will have a disease modifying effect on OA because less load to bear will reduce the rate of degeneration of the joint (I’d expect). And that’s great.
What it won’t do is reverse the process, and turn degeneration into regeneration, as we now have evidence for from 008.
I don’t see GLP-1 agonists as a major concern. They’re competitive in the same way as, say, physiotherapy or diet.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.020(4.76%) |
Mkt cap ! $174.8M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 46.0¢ | 42.0¢ | $347.2K | 796.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16968 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 2449 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |